Teva Pharmaceuticals Obtains Rights to Commercialize Polpharma's Biosimilar Candidate to Ocrevus

MT Newswires Live07-09

Teva Pharmaceutical Industries' (TEVA) Teva Pharmaceuticals International subsidiary and Polpharma Biologics said Thursday they have signed a global licensing agreement that gives Teva exclusive rights to commercialize Polpharma's proposed biosimilar to multiple sclerosis drug Ocrevus.

The licensing agreement covers both the intravenous and subcutaneous formulations of Polpharma's biosimilar candidate, the companies said.

Under the agreement, Polpharma Biologics will be responsible for the development and manufacturing of the biosimilar candidate, while Teva will be tasked with regulatory submissions and subsequent commercialization in the US, Europe, Brazil, Canada, Australia, New Zealand, Israel, and Turkey, according to a statement.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2650593922?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-09 21:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2650593922","market":"nz","top_or_hot":-1,"title":"Teva Pharmaceuticals Obtains Rights to Commercialize Polpharma's Biosimilar Candidate to Ocrevus","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/TEVA\">Teva</a> Pharmaceutical Industries' (TEVA) Teva Pharmaceuticals International subsidiary and Polpharma Biologics said Thursday they have signed a global licensing agreement that gives Teva exclusive rights to commercialize Polpharma's proposed biosimilar to multiple sclerosis drug Ocrevus.</p><p>The licensing agreement covers both the intravenous and subcutaneous formulations of Polpharma's biosimilar candidate, the companies said.</p><p>Under the agreement, Polpharma Biologics will be responsible for the development and manufacturing of the biosimilar candidate, while Teva will be tasked with regulatory submissions and subsequent commercialization in the US, Europe, Brazil, Canada, Australia, New Zealand, Israel, and Turkey, according to a statement.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teva Pharmaceuticals Obtains Rights to Commercialize Polpharma's Biosimilar Candidate to Ocrevus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeva Pharmaceuticals Obtains Rights to Commercialize Polpharma's Biosimilar Candidate to Ocrevus\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-09 21:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/TEVA\">Teva</a> Pharmaceutical Industries' (TEVA) Teva Pharmaceuticals International subsidiary and Polpharma Biologics said Thursday they have signed a global licensing agreement that gives Teva exclusive rights to commercialize Polpharma's proposed biosimilar to multiple sclerosis drug Ocrevus.</p><p>The licensing agreement covers both the intravenous and subcutaneous formulations of Polpharma's biosimilar candidate, the companies said.</p><p>Under the agreement, Polpharma Biologics will be responsible for the development and manufacturing of the biosimilar candidate, while Teva will be tasked with regulatory submissions and subsequent commercialization in the US, Europe, Brazil, Canada, Australia, New Zealand, Israel, and Turkey, according to a statement.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1983299246.USD","symbol_name":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2650593922","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2650593922","pubTimestamp":1783602548,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Teva Pharmaceutical Industries'  Teva Pharmaceuticals International subsidiary and Polpharma Biologics said Thursday they have signed a global licensing agreement that gives Teva exclusive rights to commercialize Polpharma's proposed biosimilar to multiple sclerosis drug Ocrevus.The licensing agreement covers both the intravenous and subcutaneous formulations of Polpharma's biosimilar candidate, the companies said.Under the agreement, Polpharma Biologics will be responsible for the development and manufacturing of the biosimilar candidate, while Teva will be tasked with regulatory submissions and subsequent commercialization in the US, Europe, Brazil, Canada, Australia, New Zealand, Israel, and Turkey, according to a statement.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BBP":"Virtus LifeSci Biotech Products ETF","BK4585":"ETF&股票定投概念","BK4588":"碎股","BK4557":"大麻股","TEVA":"梯瓦制药","BK4559":"巴菲特持仓","BK4596":"哈里斯概念","BK4007":"制药","BK4584":"避孕概念","BK4566":"资本集团"},"translate_title":"梯瓦制药获得Polpharma生物仿制药候选物Ocrevus商业化权利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":1.5,"BBP":0.64},"content_text":"Teva Pharmaceutical Industries' (TEVA) Teva Pharmaceuticals International subsidiary and Polpharma Biologics said Thursday they have signed a global licensing agreement that gives Teva exclusive rights to commercialize Polpharma's proposed biosimilar to multiple sclerosis drug Ocrevus.The licensing agreement covers both the intravenous and subcutaneous formulations of Polpharma's biosimilar candidate, the companies said.Under the agreement, Polpharma Biologics will be responsible for the development and manufacturing of the biosimilar candidate, while Teva will be tasked with regulatory submissions and subsequent commercialization in the US, Europe, Brazil, Canada, Australia, New Zealand, Israel, and Turkey, according to a statement.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2650593922","isCrawlerRequest":true}